Fig. 3: Kaplan Meier curves for time to next treatment (TTNT) and Overall Survival (OS) According to MRD Status in Combination with Other Disease Parameters.

A According to MRD status and PET-CT Interpretation at day 100. Patients with both MRD and PET-CT negative did not reach median TTNT. Patients who had either MRD positive or PET-CT positive had a median TTNT of 61 months; this group was mostly compromised of patients with positive MRD and negative PET-CT (79; 97%) while only a small number of patients (2; 3%) were PET-CT positive/MRD-negative. Patients who had both assessment positive had a median TTNT of 34.9 months. B Based on MRD status at day 100, and R-ISS stage at time of diagnosis. Patients with MRD negativity and R-ISS Stage I did not reach a median TTNT. Patients who had both positive MRD and Stage II or Stage III did not reach a median TTNT either. Patients with either a positive MRD or Stage II or Stage III disease had a median TTNT of 60.5 months. C According to MRD status at day 100 and genetic risk at time of diagnosis. Patients with negative MRD and standard risk genetics, and patients with negative MRD and high-risk cytogenetics did not reach median TTNT. Those with positive MRD and standard cytogenetics had a median TTNT of 60.5 months, while those with positive MRD and high-risk cytogenetics had a median TTNT of 33.1 months. D OS according to MRD assessment at day 100 and genetic risk at time of diagnosis. Only patients with positive MRD and high-risk genetics reached a median OS of 68.1 months. The other three subgroups did not reach median OS.